^
Association details:
Biomarker:ALK A348D
Cancer:Leukemia
Drug:Alunbrig (brigatinib) (EGFR inhibitor, ALK inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Source:
Title:

Therapeutically targetable ALK mutations in leukemia

Excerpt:
Treatment of ALK mutant-transformed Ba/F3 cells with AP26113 potently inhibited cell growth with an IC50 of 3 nM for the A348D mutant and 0.6 nM for the F856S mutant.
DOI:
https://dx.doi.org/10.1158%2F0008-5472.CAN-14-1576